Latus Bio Receives FDA IND Clearance for LTS-101 Gene Therapy to Treat Fatal CLN2 Disease in Children
核心洞察
Latus Bio (搜索) has received FDA IND clearance for LTS-101 (搜索), a one-time AAV gene therapy (搜索) designed to treat CLN2 disease (搜索), an ultra-rare fatal neurodegenerative disorder affecting 1 in 200,000 children worldwide.
The FDA granted LTS-101 (搜索) Fast Track, Orphan Drug, and Rare Pediatric Disease designations, providing pathways for accelerated development and potential market exclusivity benefits.
LTS-101 (搜索) utilizes a novel AAV-Ep+ capsid variant that targets ependymal cells and neurons in the central nervous system, potentially offering durable TPP1 enzyme restoration with a single low-dose injection.
Latus Bio (搜索) has achieved a significant regulatory milestone with FDA clearance of its Investigational New Drug (IND) application for LTS-101 (搜索), a gene therapy candidate targeting late-infantile neuronal ceroid lipofuscinosis type 2 (搜索) (CLN2) disease. The biotechnology company also received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, underscoring the therapy's potential to address a critical unmet medical need.
"FDA clearance of our first IND represents a major milestone for Latus," said P. Peter Ghoroghchian, M.D., Ph.D., Chief Executive Officer of Latus Bio (搜索). "The receipt of all possible FDA designations at this stage in development supports the promise of LTS-101 (搜索) to address the urgent and unmet needs of children affected by CLN2 disease (搜索)."
Addressing an Ultra-Rare Fatal Disease
CLN2 disease (搜索), a form of Batten disease (搜索), represents one of the most devastating pediatric neurodegenerative disorders, affecting approximately 1 in 200,000 children worldwide. The condition results from a lack or loss of function in the tripeptidyl peptidase 1 (搜索) (TPP1) enzyme, which is essential for breaking down and removing waste materials from neurons.
Children with CLN2 disease (搜索) typically begin showing symptoms around two years of age, experiencing developmental delays, loss of motor function, seizures, and blindness. The disease follows a relentless progression, with affected children typically dying between the ages of 8 and 12. Currently, the only approved treatment is an enzyme replacement therapy (搜索) that partially delays disease progression but requires frequent infusions via a surgically-implanted ventricular access device and is only available at select centers.
Novel Gene Therapy Approach
LTS-101 (搜索) (AAV.Ep⁺.TPP1) represents an innovative approach to treating CLN2 disease (搜索) through AAV gene therapy (搜索). The investigational treatment encodes a functional copy of the human TPP1 gene and is designed based on AAV-Ep+, a novel and proprietary AAV capsid variant that specifically targets ependymal cells and neurons in the central nervous system after intracerebroventricular (ICV) administration.
The therapy is designed as a one-time treatment intended to restore TPP1 enzyme activity to steady-state levels in the brain and spinal cord. According to Latus Bio (搜索), a single low-dose injection of LTS-101 (搜索) could provide durable benefit for children affected by CLN2 disease (搜索) and has the potential for administration at any neurosurgical center, potentially improving accessibility compared to current treatment options.
Regulatory Advantages and Development Path
The FDA's Fast Track designation provides Latus Bio (搜索) with several development advantages, including more frequent interactions with the FDA, eligibility for priority review, and potential for accelerated approval if relevant criteria are met. The Orphan Drug designation offers financial incentives, including tax credits and up to seven years of market exclusivity in the U.S. after approval.
The Rare Pediatric Disease designation provides additional benefits, making Latus eligible to receive a transferable Priority Review Voucher (PRV) if the rare pediatric disease PRV program is renewed and LTS-101 (搜索) receives approval.
Ghoroghchian emphasized that the regulatory recognition "further underscores the potential of Latus' novel AAV capsid discovery platform to yield transformative therapies that are enabled via one-time administration and at dramatically lower doses than are typically employed with conventional gene therapies."
The Philadelphia-based biotechnology company, which also maintains offices in Boston's Seaport district, is dedicated to addressing devastating CNS and peripheral diseases through gene therapy, advancing an innovative therapeutics pipeline based on novel AAV capsid variants with enhanced potency and specificity.